Milos Dokmanovic

4.4k total citations · 1 hit paper
27 papers, 3.6k citations indexed

About

Milos Dokmanovic is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Milos Dokmanovic has authored 27 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 14 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Milos Dokmanovic's work include HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Milos Dokmanovic is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Milos Dokmanovic collaborates with scholars based in United States, Sweden and Israel. Milos Dokmanovic's co-authors include Paul A. Marks, Wen Jin Wu, Lang Ngo, Igor B. Roninson, Nishant Mohan, Bey-Dih Chang, Dianne S. Hirsch, Yi Shen, Yongzhi Xuan and Eugene Kandel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Genes & Development and PLoS ONE.

In The Last Decade

Milos Dokmanovic

26 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Histone Deacetylase Inhibitors: Overview and Perspectives

2007 931 citations Milos Dokmanovic, Paul A. Marks et al. Molecular Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Milos Dokmanovic United States	19	2.9k	1.1k	305	248	228	27	3.6k
Yasuhisa Fukui Japan	35	3.4k 1.2×	801 0.7×	181 0.6×	459 1.9×	310 1.4×	85	4.5k
Hiroshi Yasui Japan	31	3.0k 1.0×	1.3k 1.2×	209 0.7×	549 2.2×	415 1.8×	141	4.7k
Esther Zwick Germany	11	2.3k 0.8×	1.2k 1.1×	173 0.6×	350 1.4×	388 1.7×	12	3.7k
James F. Callahan United States	22	2.7k 0.9×	691 0.6×	157 0.5×	325 1.3×	359 1.6×	54	4.0k
Laurens A. van Meeteren Netherlands	27	3.0k 1.0×	358 0.3×	491 1.6×	312 1.3×	301 1.3×	33	3.8k
Alexandre Arcaro Switzerland	31	2.6k 0.9×	659 0.6×	215 0.7×	761 3.1×	351 1.5×	51	3.9k
Oliver M. Fischer Germany	16	1.4k 0.5×	1.1k 1.0×	265 0.9×	231 0.9×	305 1.3×	25	2.8k
Dimcho Bachvarov Canada	34	1.9k 0.7×	582 0.5×	223 0.7×	777 3.1×	439 1.9×	91	3.9k
Thorsten Maretzky United States	25	2.0k 0.7×	1.1k 1.0×	269 0.9×	536 2.2×	457 2.0×	47	3.6k
Yonghe Li United States	35	2.4k 0.8×	807 0.7×	289 0.9×	340 1.4×	715 3.1×	57	3.7k

Countries citing papers authored by Milos Dokmanovic

Since Specialization

Citations

This map shows the geographic impact of Milos Dokmanovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milos Dokmanovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milos Dokmanovic more than expected).

Fields of papers citing papers by Milos Dokmanovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Milos Dokmanovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milos Dokmanovic. The network helps show where Milos Dokmanovic may publish in the future.

Co-authorship network of co-authors of Milos Dokmanovic

This figure shows the co-authorship network connecting the top 25 collaborators of Milos Dokmanovic. A scholar is included among the top collaborators of Milos Dokmanovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milos Dokmanovic. Milos Dokmanovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mohan, Nishant, Yi Shen, Yukinori Endo, et al.. (2022). Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1. Pharmaceutics. 14(7). 1381–1381. 2 indexed citations

Dokmanovic, Milos, Kathryn E. King, Nishant Mohan, Yukinori Endo, & Wen Jin Wu. (2017). Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab. Expert Opinion on Drug Metabolism & Toxicology. 13(7). 755–766. 18 indexed citations

Mohan, Nishant, Yi Shen, Milos Dokmanovic, et al.. (2016). VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformation. Oncotarget. 7(32). 52239–52254. 24 indexed citations

Yan, Haoheng, Yukinori Endo, Yi Shen, et al.. (2015). Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. Molecular Cancer Therapeutics. 15(3). 480–490. 52 indexed citations

Dokmanovic, Milos & Wen Jin Wu. (2015). Monitoring Trastuzumab Resistance and Cardiotoxicity. Advances in clinical chemistry. 70. 95–130. 14 indexed citations

Dokmanovic, Milos, Yun Wu, Yi Shen, et al.. (2014). Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition. Cancer Biology & Therapy. 15(8). 1029–1041. 46 indexed citations

Hirsch, Dianne S., Yi Shen, Milos Dokmanovic, et al.. (2014). Insulin activation of vacuolar protein sorting 34 mediates localized phosphatidylinositol 3-phosphate production at lamellipodia and activation of mTOR/S6K1. Cellular Signalling. 26(6). 1258–1268. 16 indexed citations

ElZarrad, M. Khair, Partha Mukhopadhyay, Nishant Mohan, et al.. (2013). Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice. PLoS ONE. 8(11). e79543–e79543. 106 indexed citations

Bonacci, Tabetha M., Dianne S. Hirsch, Yi Shen, Milos Dokmanovic, & Wen Jin Wu. (2012). Small GTPase Rho regulates R-cadherin through Dia1/profilin-1. Cellular Signalling. 24(11). 2102–2110. 10 indexed citations

10.

Dokmanovic, Milos, Yi Shen, Tabetha M. Bonacci, Dianne S. Hirsch, & Wen Jin Wu. (2011). Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance. Molecular Cancer Therapeutics. 10(6). 917–928. 21 indexed citations

11.

Dokmanovic, Milos, et al.. (2007). Histone deacetylase inhibitors selectively suppress expression of HDAC7. Molecular Cancer Therapeutics. 6(9). 2525–2534. 84 indexed citations

12.

Dokmanovic, Milos, et al.. (2007). Histone Deacetylase Inhibitors: Overview and Perspectives. Molecular Cancer Research. 5(10). 981–989. 931 indexed citations breakdown →

13.

Ingvarsdottir, Kristin, David E. Sterner, Milos Dokmanovic, et al.. (2006). Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes & Development. 20(8). 966–976. 234 indexed citations

14.

Xu, Weisheng, et al.. (2006). Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proceedings of the National Academy of Sciences. 103(42). 15540–15545. 157 indexed citations

15.

Marks, Paul A. & Milos Dokmanovic. (2005). Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opinion on Investigational Drugs. 14(12). 1497–1511. 263 indexed citations

16.

Dokmanovic, Milos & Paul A. Marks. (2005). Prospects: Histone deacetylase inhibitors. Journal of Cellular Biochemistry. 96(2). 293–304. 405 indexed citations

17.

Dokmanovic, Milos. (2003). Growth inhibitory targets of retinoids.. Figshare. 1 indexed citations

18.

Roninson, Igor B. & Milos Dokmanovic. (2002). Induction of senescence‐associated growth inhibitors in the tumor‐suppressive function of retinoids. Journal of Cellular Biochemistry. 88(1). 83–94. 34 indexed citations

19.

Dokmanovic, Milos, Bey-Dih Chang, Jing Fang, & Igor B. Roninson. (2002). Retinoid-Induced Growth Arrest of Breast Carcinoma Cells Involves Co-Activation of Multiple Growth-Inhibitory Genes. Cancer Biology & Therapy. 1(1). 24–27. 58 indexed citations

20.

Chang, Bey-Dih, Eugenia V. Broude, Milos Dokmanovic, et al.. (1999). A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.. PubMed. 59(15). 3761–7. 459 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact